Systemic Treatment of Stage IV (Advanced/Metastatic) Anal Cancer in Patients Fit for Chemotherapy

Clinical Scenario

This protocol addresses patients with stage IV (advanced or metastatic) anal cancer who are fit and eligible for systemic treatment. It covers symptomatic metastatic or recurrent disease that is not amenable to surgical management.

Patient Eligibility

Otherwise fit patients with symptomatic metastatic or recurrent anal cancer not amenable to surgery are candidates for systemic chemotherapy as the primary treatment approach.

Treatment Approach

First-line management involves a platinum-based combination chemotherapy regimen. The complete regimen, sequencing, and decision algorithm are detailed in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

Eligible for systemic treatment
Otherwise fit patients with symptomatic metastatic or recurrent disease not amenable to surgery should be considered for ChT.
First-line: carboplatin–paclitaxel [I, B]
Carboplatin in combination with paclitaxel should be considered a new standard of care in patients with ChT-naive advanced anal cancer [I, B].

DOI: 10.1016/j.annonc.2021.06.015

View source ↗